Skip to main content
. 2016 Apr 29;90(10):5031–5046. doi: 10.1128/JVI.03211-15

TABLE 2.

Inhibition of primary HIV-1 Env isolates by CD4-mimetic compounds in the presence of 17b CD4i antibody or plasma from immunized monkeys

Antibody/compound IC50 fora:
HIV-1JR-FL HIV-1YU2 HIV-1AD8 A-MLV
BNM-III-170b 17.4 μM 1.9 μM 3.6 μM >100 μM
17b >30 μg/ml >30 μg/ml >30 μg/ml >30 μg/ml
NHP 79-5356, wk 21 >1:80 >1:80 >1:80 1:160
NHP 62.1-5097, wk 123 >1:80 >1:80 >1:80 1:160
NHP 109-6117, wk 71 >1:80 >1:80 >1:80 >1:80
NHP 109-6204, wk 71 >1:80 >1:80 >1:80 1:160
17b + BNM-III-170 0.2 μg/ml <0.2 μg/ml 0.2 μg/ml >30 μg/ml
NHP 79-5356, wk 21, + BNM-III-170 1:320 1:640 1:640 1:80
NHP 62.1-5097, wk 123, + BNM-III-170 1:640 1:1,280 1:1,280 >1:80
NHP 109-6117, wk 71, + BNM-III-170 1:1,280 1:1,280 1:1,280 >1:80
NHP 109-6204, wk 71, + BNM-III-170 1:640 1:1,280 1:1,280 1:160
a

Recombinant HIV-1 encoding firefly luciferase was pseudotyped with the indicated HIV-1 Env (or A-MLV Env control), as described in the footnotes to Table 1. Viruses were incubated with 10 μM BNM-III-170 (YU2 and AD8), 50 μM BNM-III-170 (JR-FL and A-MLV), or DMSO and then with different concentrations of the 17b antibody or dilution of plasma. The nonhuman primates (NHP) 6117 and 6204 were subjects in CHAVI-ID NHP 109, and both were members of group 1, which received basiliximab (1 mg) after immunization with CH505 T/F gp120 in GLA-SE adjuvant. The concentration of the 17b antibody (μg/ml) or the titer of the plasma that neutralized 50% of the virus infection is indicated. Means and standard deviations from triplicate samples within an experiment are shown.

b

The inhibitory concentration (IC50) for the direct antiviral effect of BNM-III-170 was determined as described in footnote a.